Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$324.70|
|52 Week High||US$201.44|
|52 Week Low||US$333.96|
|1 Month Change||0.98%|
|3 Month Change||20.86%|
|1 Year Change||56.75%|
|3 Year Change||200.59%|
|5 Year Change||318.27%|
|Change since IPO||33,417.42%|
Recent News & Updates
If You Like EPS Growth Then Check Out Danaher (NYSE:DHR) Before It's Too Late
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Estimating The Fair Value Of Danaher Corporation (NYSE:DHR)
Does the August share price for Danaher Corporation ( NYSE:DHR ) reflect what it's really worth? Today, we will...
Danaher's Growth Machine Keeps On Roaring, With No Slowdown In Sight For Bioproduction
The Street expected a strong quarter from Danaher, and they got that and more, with strong growth across the business and significant margin leverage. Bioproduction remains a once-in-a-generation growth opportunity where Danaher has bought its leadership, including the recent deal for Aldevron to build up its plasmid DNA capabilities. PCR-based COVID-19 testing has remained strong for Cepheid, and the company is likewise leveraging pandemic-driven system placements across its full set of test offerings. EAS is recovering nicely, with particularly good growth in Product ID, but this business remains a sale/spin-off candidate. Danaher doesn't really lend itself to sober-minded quantitative valuation approaches, but the growth set-up remains top-notch.
|DHR||US Medical Equipment||US Market|
Return vs Industry: DHR exceeded the US Medical Equipment industry which returned 34.6% over the past year.
Return vs Market: DHR exceeded the US Market which returned 33% over the past year.
Stable Share Price: DHR is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: DHR's weekly volatility (2%) has been stable over the past year.
About the Company
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Danaher Fundamentals Summary
|DHR fundamental statistics|
Is DHR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DHR income statement (TTM)|
|Cost of Revenue||US$10.60b|
Last Reported Earnings
Jul 02, 2021
Next Earnings Date
|Earnings per share (EPS)||7.52|
|Net Profit Margin||20.06%|
How did DHR perform over the long term?See historical performance and comparison
0.3%Current Dividend Yield
Does DHR pay a reliable dividends?See DHR dividend history and benchmarks
|Danaher dividend dates|
|Ex Dividend Date||Sep 29 2021|
|Dividend Pay Date||Oct 29 2021|
|Days until Ex dividend||7 days|
|Days until Dividend pay date||37 days|
Does DHR pay a reliable dividends?See DHR dividend history and benchmarks
Is Danaher undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: DHR ($324.7) is trading above our estimate of fair value ($254.66)
Significantly Below Fair Value: DHR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: DHR is good value based on its PE Ratio (43.2x) compared to the US Medical Equipment industry average (52.5x).
PE vs Market: DHR is poor value based on its PE Ratio (43.2x) compared to the US market (17.5x).
Price to Earnings Growth Ratio
PEG Ratio: DHR is poor value based on its PEG Ratio (10.9x)
Price to Book Ratio
PB vs Industry: DHR is overvalued based on its PB Ratio (5.9x) compared to the US Medical Equipment industry average (4.6x).
How is Danaher forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DHR's forecast earnings growth (4% per year) is above the savings rate (2%).
Earnings vs Market: DHR's earnings (4% per year) are forecast to grow slower than the US market (14.9% per year).
High Growth Earnings: DHR's earnings are forecast to grow, but not significantly.
Revenue vs Market: DHR's revenue (5.7% per year) is forecast to grow slower than the US market (9.8% per year).
High Growth Revenue: DHR's revenue (5.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DHR's Return on Equity is forecast to be low in 3 years time (13.5%).
How has Danaher performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DHR has high quality earnings.
Growing Profit Margin: DHR's current net profit margins (20.1%) are higher than last year (15.1%).
Past Earnings Growth Analysis
Earnings Trend: DHR's earnings have grown by 15.5% per year over the past 5 years.
Accelerating Growth: DHR's earnings growth over the past year (88.1%) exceeds its 5-year average (15.5% per year).
Earnings vs Industry: DHR earnings growth over the past year (88.1%) exceeded the Medical Equipment industry 40.5%.
Return on Equity
High ROE: DHR's Return on Equity (12.9%) is considered low.
How is Danaher's financial position?
Financial Position Analysis
Short Term Liabilities: DHR's short term assets ($15.4B) exceed its short term liabilities ($6.8B).
Long Term Liabilities: DHR's short term assets ($15.4B) do not cover its long term liabilities ($28.4B).
Debt to Equity History and Analysis
Debt Level: DHR's debt to equity ratio (47.8%) is considered high.
Reducing Debt: DHR's debt to equity ratio has reduced from 57.9% to 47.8% over the past 5 years.
Debt Coverage: DHR's debt is well covered by operating cash flow (38.9%).
Interest Coverage: DHR's interest payments on its debt are well covered by EBIT (27.5x coverage).
What is Danaher current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: DHR's dividend (0.26%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.35%).
High Dividend: DHR's dividend (0.26%) is low compared to the top 25% of dividend payers in the US market (3.65%).
Stability and Growth of Payments
Stable Dividend: DHR is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: DHR is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: DHR is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DHR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rainer Blair (57 yo)
Mr. Rainer M. Blair serves as President, Chief Executive Officer and Director at Danaher Corporation since September 1, 2020. Mr. Blair served as an Executive Vice President of Danaher Corporation since Ja...
CEO Compensation Analysis
Compensation vs Market: Rainer's total compensation ($USD10.40M) is about average for companies of similar size in the US market ($USD11.33M).
Compensation vs Earnings: Rainer's compensation has increased by more than 20% in the past year.
Experienced Management: DHR's management team is considered experienced (4.7 years average tenure).
Experienced Board: DHR's board of directors are seasoned and experienced ( 11.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DHR insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Danaher Corporation's employee growth, exchange listings and data sources
- Name: Danaher Corporation
- Ticker: DHR
- Exchange: NYSE
- Founded: 1969
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$231.803b
- Shares outstanding: 713.90m
- Website: https://www.danaher.com
Number of Employees
- Danaher Corporation
- 2200 Pennsylvania Avenue, NW
- Suite 800W
- District Of Columbia
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/22 00:11|
|End of Day Share Price||2021/09/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.